uniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 12,378 Shares

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 12,378 shares of uniQure stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $295,339.08. Following the completion of the transaction, the chief executive officer directly owned 639,076 shares in the company, valued at approximately $15,248,353.36. This represents a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

uniQure Stock Performance

NASDAQ:QURE opened at $15.63 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure N.V. has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The company has a 50 day simple moving average of $23.46 and a two-hundred day simple moving average of $29.59. The company has a market capitalization of $973.59 million, a PE ratio of -3.56 and a beta of 0.66.

Wall Street Analyst Weigh In

A number of analysts have commented on QURE shares. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of uniQure in a research report on Thursday. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. William Blair reiterated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Finally, Barclays assumed coverage on shares of uniQure in a research report on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average price target of $58.33.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently made changes to their positions in QURE. Private Trust Co. NA bought a new position in uniQure in the 3rd quarter valued at about $28,000. Jones Financial Companies Lllp lifted its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC bought a new position in shares of uniQure in the third quarter valued at approximately $50,000. Torren Management LLC purchased a new position in shares of uniQure during the fourth quarter valued at approximately $28,000. Finally, FNY Investment Advisers LLC grew its holdings in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Unusual bullish options flow — heavy call buying (24,345 calls, ~181% above typical volume) suggests some traders are speculating on a near‑term rebound or event‑driven move.
• Negative Sentiment: Fresh FDA controversy: coverage highlights critical comments from FDA leadership about uniQure’s rejected rare‑disease therapy, which markets see as increasing regulatory risk for the program. uniQure: Shares Tumble On Fresh FDA Controversy – What Investors Should Know
• Negative Sentiment: FDA commissioner comments drew broad media coverage and were cited as the main driver of the selloff, amplifying short‑term downside as investors reassess approval odds. UniQure plummets as FDA’s Marty Makary disparages rejected rare disease drug
• Negative Sentiment: Multiple securities‑class action filings and firm notices: several law firms are publicizing suits or seeking lead plaintiffs for alleged misstatements during a specified class period — increasing legal and reputational risk and likely weighing on sentiment. Representative notices: DJS Law Group. uniQure N.V. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – QURE
• Negative Sentiment: Broad wave of law‑firm alerts and reminder notices (Rosen, Pomerantz, Faruqi, Robbins, Berger Montague, etc.) highlights that litigation momentum is building and that April 13, 2026 lead‑plaintiff deadlines are approaching — an added near‑term overhang. Example: Rosen Law Firm reminder. ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action – QURE
• Negative Sentiment: Market reaction summaries: analyst/news pieces attribute a large intraday drop to the FDA remarks and resulting uncertainty, reinforcing negative sentiment. Why Is uniQure Stock Down 30% Today?

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.